Diabetes Mellitus, Periodontal Pocket, Periodontitis
Conditions
Keywords
periodontitis, diabetes mellitus, systemic antimicrobials
Brief summary
Periodontitis is an inflammation of the supporting structures of the teeth, usually caused by specific or groups of microorganisms that results in the progressive destruction of the periodontal ligament and alveolar bone. the objective of periodontitis treatment is to reduce the number of periodontal pathogens. However, there is not an agreement in the use of systemic antibiotics in patients with diabetes. The purpose of the present study was to determine the efficacy of amoxicillin/metronidazole compared to clindamycin during non-surgical treatment of periodontitis in patients with type 2 diabetes mellitus. Patients and methods In this double-blind, randomized clinical trial, a total of 42 patients with chronic periodontitis and type 2 diabetes were included in a 24-months follow-up. Patients were randomly assigned to treatment with either amoxicillin/metronidazole or clindamycin every for 7 days. Clinical determinations (depth of probing, bleeding at the probe and plaque index) were performed to determine the extent and severity of periodontitis before and after the pharmacological treatment. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant
Detailed description
A parallel, randomized, double-blind, active controlled, single center clinical trial was designed to compare the efficacy of two antibiotic therapies with 24-month follow-up. The study protocol was approved by the ethical committee of the Universitary Center of Health Sciences of University of Guadalajara and conducted according to Good Clinical Practice and the principles of the Declaration of Helsinki. All patients provided written informed consent before the initiation of study procedures. A total of 5 non-study subjects with chronic periodontitis were recruited and used for the calibration exercise. Two designated examiners measured full-mouth probing pockets depths (PPD) for all 5 subjects. On the same day (with a minimum of 15 min separation), the examiner repeated the examination. Upon completion of all measurements, the intra-examiner repeatability for PPD measurement was assessed. The examiner was judged to be reproducible after fulfilling the pre-determined success criteria (the percentage of agreement within 2 mm between repeated measurements had to be at least 70 %). The examiner showed 78.3 % reproducibility. The sample size was calculated with a 95% confidence level and statistical power of 80 %. A standard deviation of 1.0 mm with an expected difference of 1.0 mm probing pocket depth reduction between treatments. This resulted in a total of 14 patients per arm, however this sample was increased 20% (21 patients per group) to compensate for possible dropouts. Patient population Criteria for selection Patients of both sexes (aged \>18 to 70 years) with a diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions and a history of type 2 diabetes with a HbA1C \< 8 % and a fasting plasma glucose (FPG) \< 180 mg/dL. Patients with aggressive periodontitis, pregnant or lactating females, required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded. A history of anti-inflammatory therapy within preceding six months or that had received a course of periodontal treatment within the last 6 months, allergies to penicillin, metronidazole or clindamycin, and were not able to provide consent to participate in the study were also criteria for exclusion. Intervention Subjects were randomly allocated 1:1 to receive 500 mg amoxicillin + 250 mg metronidazole or 300 mg clindamycin + placebo using a computer that generated a list of random numbers. Subjects were instructed to take the treatment three times a day for 7 days in both groups. Assessments During these sessions, a case presentation was given to each subject related to the specific features of his/her disease, as well as a supra- and sub-gingival mechanical debridement was performed. A complete periodontal examination was performed, including a full medical and dental history, an intra-oral examination and a full-mouth periodontal probing. A radiographic examination was undertaken using either periapical x-rays or a ortopantomography. Clinical parameters Clinical parameters were assessed using a North Caroline Periodontal Probe by the calibrated examiner at six sites. Full-mouth plaque scores were recorded by assigning a binary score to each surface (1 for plaque present, 0 for absent) and by calculating the percentage of total tooth surfaces that revealed the presence of plaque detected by the use of tablet. Similarly, a full-mouth percentage bleeding score was calculated after assessing dichotomously the presence of bleeding on probing from the bottom of the pocket when probing with a manual probe with a force of 0.3n. Full-mouth PPD and recession of the gingival margin were recorded at the same time with measurements rounded to the nearest millimeter. Non-surgical periodontal therapy Periodontal therapy was initiated within 1 month of the baseline screening examination. A standard cycle of periodontal therapy consisting of oral hygiene instructions, supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planning) was performed by two experienced therapists. Local anesthesia was used as necessary. Patients relied on standard oral hygiene methods as instructed at the commencement of the study. Post-treatment controls The objectives of the post-treatment appointments were to control and reinforce the oral hygiene habits of each subject, to monitor the early healing events and to report any adverse events or additional medications taken. In addition, the 1-week post-treatment visit served as a compliance control, as subjects were asked to return any medication not taken and/or the empty bottles. The number of pills not taken by the study subjects was documented. Re-assessment examinations Reassessment visits occurred within a month and a half of the completion of the pharmacological treatment. During these appointments, the examiner recorded any changes in the medical history and repeated clinical periodontal parameters recorded at the basal visit. Statistical analysis Age, FPG, HbA1C, tooth, and sounding depth were presented in means and standard deviation. The intra-group differences were calculated with Wilcoxon rank test. The inter-group differences were calculated with Mann-Whitney test. Sex, bacterial plaque, and bleed to the sounding were summarized using proportions and analyzed with the chi-square method. In all analyses, a P-value of \<0.05 (two tailed) was considered statistically significant. All statistical analyses were conducted using SPSS software (IBM Corporation, Armonk, NY, USA) version 21.
Interventions
Subjects were instructed to take a capsule three times a day for 7 days
Subjects were instructed to take a capsule three times a day for 7 days
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients of both sexes * Age \>18 to 70 years * Diagnosis of chronic periodontitis according to the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions * History of type 2 diabetes * HbA1C \< 8 % * Fasting plasma glucose (FPG) \< 180 mg/dL.
Exclusion criteria
* Aggressive periodontitis * Pregnant or lactating females, * Required antibiotic pre-medication for the performance of periodontal examination and treatment or received antibiotic treatment in the previous 3 months were excluded. * A history of anti-inflammatory therapy within preceding six months * Had received a course of periodontal treatment within the last 6 months, * Allergies to penicillin, metronidazole or clindamycin, * Not able to provide consent to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Probing Depth | 7 days | The size of the periodontal pocket |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sites With Plaques | 7 days | 0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome |
| Sites With Bleeding on Probing | 7 days | Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration |
| Total Count of All Teeth Lost Across All Participants | 2 years | The total count of all teeth lost in all participants. |
Participant flow
Recruitment details
The study was carried out on patients at the Integral Dentistry Clinics of the University Center of Health Sciences of the University of Guadalajara in Jalisco, Mexico. The participants attended for dental care from August 2015 to December 2016.
Pre-assignment details
A radiographic examination was undertaken using either periapical films or a pantomogram. Periodontal therapy was initiated within 1month of the baseline screening examination.
Participants by arm
| Arm | Count |
|---|---|
| AMX-MET 500 mg amoxicillin plus 250 mg metronidazole three times a day for 7days | 21 |
| Clindamycin 300mg clindamycin plus placebo three times a day for 7days | 21 |
| Total | 42 |
Baseline characteristics
| Characteristic | AMX-MET | Clindamycin | Total |
|---|---|---|---|
| Age, Continuous | 52.5 years STANDARD_DEVIATION 8 | 52.0 years STANDARD_DEVIATION 10.6 | 52.2 years STANDARD_DEVIATION 9.3 |
| Bleeding on Probing | 42.4 Sites STANDARD_DEVIATION 24.2 | 55.6 Sites STANDARD_DEVIATION 25.8 | 49.0 Sites STANDARD_DEVIATION 25.6 |
| Fasting Plasma Glucose | 134.1 mg/dL STANDARD_DEVIATION 23.3 | 136.3 mg/dL STANDARD_DEVIATION 25.7 | 135.2 mg/dL STANDARD_DEVIATION 24.2 |
| HbA1C | 7.1 % STANDARD_DEVIATION 0.4 | 7.3 % STANDARD_DEVIATION 0.4 | 7.2 % STANDARD_DEVIATION 0.4 |
| Number of Teeth present in the subjects | 25 Teeth STANDARD_DEVIATION 3 | 24 Teeth STANDARD_DEVIATION 5 | 24 Teeth STANDARD_DEVIATION 4 |
| Probing depth | 2.4 mm STANDARD_DEVIATION 0.6 | 2.6 mm STANDARD_DEVIATION 0.6 | 2.5 mm STANDARD_DEVIATION 0.6 |
| Sex: Female, Male Female | 10 Participants | 14 Participants | 24 Participants |
| Sex: Female, Male Male | 11 Participants | 7 Participants | 18 Participants |
| Sites with Plaque | 40.4 Sites STANDARD_DEVIATION 22.9 | 40.7 Sites STANDARD_DEVIATION 21.9 | 40.5 Sites STANDARD_DEVIATION 22.1 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 21 |
| other Total, other adverse events | 0 / 21 | 0 / 21 |
| serious Total, serious adverse events | 0 / 21 | 0 / 21 |
Outcome results
Probing Depth
The size of the periodontal pocket
Time frame: 7 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AMX-MET | Probing Depth | 0.44 mm | Standard Deviation 0.27 |
| Clindamycin | Probing Depth | 0.50 mm | Standard Deviation 0.17 |
Sites With Bleeding on Probing
Refers to bleeding on probing 0: absence of inflammation 1. mild inflammation; a slight change in color, little change in the texture of any portion of but not the entire marginal or papillary gingival unit 2. mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit 3. moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit 4; severe inflammation; marked redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Time frame: 7 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AMX-MET | Sites With Bleeding on Probing | 16.1 Sites | Standard Deviation 11.2 |
| Clindamycin | Sites With Bleeding on Probing | 22.1 Sites | Standard Deviation 12.9 |
Sites With Plaques
0: no plaque 1. separate flecks of plaque at the cervical margin of the tooth 2. a thin continuous band of plaque (up to 1 mm) at the cervical margin of the tooth 3. a continuous band of plaque wider than 1 mm but covering less than one-third of the crown of the tooth 4. plaque covering at least one-third but less than two-thirds of the crown of the tooth 5. plaque covering two-thirds or more of the crown of the tooth. A higher scores mean a worse outcome
Time frame: 7 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AMX-MET | Sites With Plaques | 17.6 Sites | Standard Deviation 13.3 |
| Clindamycin | Sites With Plaques | 15.8 Sites | Standard Deviation 10 |
Total Count of All Teeth Lost Across All Participants
The total count of all teeth lost in all participants.
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AMX-MET | Total Count of All Teeth Lost Across All Participants | 0 total count of all teeth lost |
| Clindamycin | Total Count of All Teeth Lost Across All Participants | 0 total count of all teeth lost |